Wyeth's profit rose 13% on cost cutting while strong sales of its Prevnar pneumococcal vaccine nearly offset declines for its top-selling antidepressant Effexor. The drug maker also boosted its 2009 outlook.
WSJ.com: What's News US, Wall Street Journal: Home US
Thu, 07/23/2009 - 4:57am
Wyeth's profit rose 13% on cost cutting while strong sales of its Prevnar pneumococcal vaccine nearly offset declines for its top-selling antidepressant Effexor. The drug maker also boosted its 2009 outlook.